On September 12, 2017, Ceciel Rooker presented the following research information to the US Food and Drug Administration (FDA) concerning the burdens and needs of gastroparesis patients:

On behalf of the International Foundation for Functional Gastrointestinal Disorders (IFFGD), we appreciate the opportunity provided by the FDA to hear the patient perspective at the Patient-Focused Drug Development public meeting on Functional GI Disorders held on May 11, 2015.

I am pleased to follow-up on our participation at that meeting and share with you the results of a peer-reviewed online survey we conducted in collaboration with investigators from Temple University School of Medicine. The data from this research looks at burdens, concerns, and quality of life of 1,423 adults in the general community diagnosed with gastroparesis. Attached (PDF) is a Summary Report. The full study results were published in the journal, Digestive Diseases and Sciences (Yu D, Ramsey FV, et al. The burdens, concerns, and quality of life of patients with gastroparesis. Dig Dis Sci. 2017 Jan 12. doi:10.1007/s10620-017-4456-7).

We appreciate your continuing efforts at the FDA to learn the perspective of patients as you seek to understand and help meet the needs of people with gastroparesis and other functional GI disorders. Thank you.

 

About IFFGD
Leadership
Nancy J. Norton, IFFGD Founder
Ceciel T. Rooker, IFFGD President
Advisory Board
Officers and Board of Directors
Editorial Board Members
Our Mission
Awareness Activities & Accomplishments
Public Education & Awareness
Professional Education & Awareness
Year in Review
-2017
-2015
-2014
-2012/2013
Advocacy Activities
Legislative Successes
FGIMD Act (Functional Gastrointestinal and Motility Disorders Research Enhancement Act)
Congressional Testimony
FISCAL YEAR 2019
FISCAL YEAR 2013
FISCAL YEAR 2012
FISCAL YEAR 2010
FISCAL YEAR 2009
FISCAL YEAR 2008
FISCAL YEAR 2007
FISCAL YEAR 2006
FISCAL YEAR 2005
FISCAL YEAR 2004
FISCAL YEAR 2003
FISCAL YEAR 2016
FDA and Other Testimony
Written Comments to FDA October 18, 2018
Written Comments to FDA October 17, 2018
Written Presentation to FDA September 12, 2017
Written Comments to FDA June 29, 2015
Oral Comments to FDA May 11, 2015
Comments to FDA July 16th, 2014
Written Comments to Noridian October 24, 2013
Testimony to FDA October 25, 2012
Testimony to FDA September 12, 2012
Testimony to FDA December 13, 2011
Testimony to FDA December 2, 2010
Testimony to FDA April 23, 2002
Comments to FDA November 9, 2000
Testimony to FDA June 27, 2000
Testimony to FDA June 26, 2000
Capitol Hill Advocacy Day
Research
IFFGD Research Awards
IFFGD Symposium reports
2013 Professional Symposium
10th Symposium Report
10th Symposium Audio Recordings
More from the 10th Symposium on FGIDs
2011 Professional Symposium
9th Symposium Report
2009 Professional Symposium
2007 Professional Symposium
7th Symposium Report
2005 Professional Symposium
6th Symposium Report
2003 Professional Symposium
5th Symposium Report
2002 Conference - Advancing the Treatment of Incontinence
Funding
Corporate Support
Our Research Funding Needs
IFFGD Standards for Collaboration
Industry Council
Code of Ethics
Contact Us
Media Contact
Donation
Have You Heard? It Could Be GERD!

Advocate for Change

capital hill day 2

What it means to be an advocate – someone who speaks out and works with others to create meaningful, positive change. Let your voice be heard.

Taking Action for Digestive Health

The Functional GI and Motility Disorders Research Enhancement Act

Make Your Voice Heard